HDL as a target in the treatment of atherosclerotic cardiovascular disease

[1]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[2]  P. Linsel-Nitschke,et al.  HDL as a target in the treatment of atherosclerotic cardiovascular disease , 2005, Nature Reviews Drug Discovery.

[3]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ , 2004 .

[4]  O. Schober,et al.  High-Density Lipoprotein Stimulates Myocardial Perfusion In Vivo , 2004, Circulation.

[5]  G. Anantharamaiah,et al.  D-4F, an Apolipoprotein A-I Mimetic Peptide, Inhibits the Inflammatory Response Induced by Influenza A Infection of Human Type II Pneumocytes , 2004, Circulation.

[6]  B. Nordestgaard,et al.  Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. , 2004, The Journal of clinical investigation.

[7]  Sungshin Y. Choi,et al.  Endothelial Lipase Modulates Susceptibility to Atherosclerosis in Apolipoprotein-E-deficient Mice* , 2004, Journal of Biological Chemistry.

[8]  S. Kaul,et al.  Differential Effects of Apolipoprotein A-I–Mimetic Peptide on Evolving and Established Atherosclerosis in Apolipoprotein E-Null Mice , 2004, Circulation.

[9]  E. Ghigo,et al.  Dual effects of IGFBP‐3 on endothelial cell apoptosis and survival: Involvement of the sphingolipid signaling pathways , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  E. Fisher,et al.  Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Jonathan C. Cohen,et al.  Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol , 2004, Science.

[12]  T. Kirchgessner,et al.  Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator Published, JLR Papers in Press, June 1, 2004. DOI 10.1194/jlr.M300450-JLR200 , 2004, Journal of Lipid Research.

[13]  A. Tall,et al.  ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Rader,et al.  Endothelial Lipase Promotes the Catabolism of ApoB-Containing Lipoproteins , 2004, Circulation research.

[15]  J. Yano,et al.  A Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), Potently Decreases Plasma Triglyceride and Glucose Levels and Modifies Lipoprotein Profiles in KK-Ay Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  M. Saad,et al.  Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. , 2004, Diabetes care.

[17]  A. Tall,et al.  A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly Published, JLR Papers in Press, February 16, 2004. DOI 10.1194/jlr.M300520-JLR200 , 2004, Journal of Lipid Research.

[18]  D. Rader,et al.  Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. , 2004, The New England journal of medicine.

[19]  J. Auwerx,et al.  Expression of the liver X receptor α and β in embryonic and adult mice , 2004 .

[20]  T. Warner,et al.  Expression and activation of the farnesoid X receptor in the vasculature. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Accili,et al.  Increased CD36 protein as a response to defective insulin signaling in macrophages. , 2004, The Journal of clinical investigation.

[22]  G. Assmann,et al.  HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. , 2004, The Journal of clinical investigation.

[23]  M. Trottmann,et al.  Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. , 2004, Biochemical pharmacology.

[24]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[25]  A. Mrhar,et al.  Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. , 2003, International journal of clinical pharmacology and therapeutics.

[26]  D. Rader.  High-density lipoproteins as an emerging therapeutic target for atherosclerosis. , 2003, JAMA.

[27]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[28]  M. Linton,et al.  Inactivation of Macrophage Scavenger Receptor Class B Type I Promotes Atherosclerotic Lesion Development in Apolipoprotein E–Deficient Mice , 2003, Circulation.

[29]  P. Drake,et al.  Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes , 2003 .

[30]  A. Tall,et al.  Retinoic Acid Receptor-Mediated Induction of ABCA1 in Macrophages , 2003, Molecular and Cellular Biology.

[31]  J. Tayek,et al.  Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[32]  C. Montrose‐Rafizadeh,et al.  Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor α agonist , 2003 .

[33]  R. Chakrabarti,et al.  Ragaglitazar: a novel PPARα & PPARγ agonist with potent lipid‐lowering and insulin‐sensitizing efficacy in animal models , 2003 .

[34]  K. Maki,et al.  The safety and immunogenicity of a CETP vaccine in healthy adults. , 2003, Atherosclerosis.

[35]  Koichi Sato,et al.  High-Density Lipoprotein Stimulates Endothelial Cell Migration and Survival Through Sphingosine 1-Phosphate and Its Receptors , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[36]  J. Menke,et al.  Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[37]  Xiang-An Li,et al.  HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. , 2003, The Journal of clinical investigation.

[38]  C. Kahn,et al.  The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. , 2003, The Journal of clinical investigation.

[39]  C. Heng,et al.  ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore , 2003, Human Genetics.

[40]  R. Evans,et al.  Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity , 2003, Cell.

[41]  M. Bowman,et al.  A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. , 2003, Molecular cell.

[42]  J. Sturis,et al.  Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats , 2003 .

[43]  S. Dowell,et al.  Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid* , 2003, The Journal of Biological Chemistry.

[44]  A. Rigotti,et al.  Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice* , 2003, The Journal of Biological Chemistry.

[45]  P. J. Larsen,et al.  PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly , 2003 .

[46]  D. Rader,et al.  Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. , 2003, The Journal of clinical investigation.

[47]  K. Bramlett,et al.  A Chemical Switch Regulates Fibrate Specificity for Peroxisome Proliferator-activated Receptor α (PPARα) VersusLiver X Receptor* , 2003, The Journal of Biological Chemistry.

[48]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[49]  P. J. Larsen,et al.  Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. , 2003, Diabetes.

[50]  P. Linsel-Nitschke,et al.  A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. , 2003, The Journal of clinical investigation.

[51]  E. Schaefer,et al.  Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. , 2002, The American journal of cardiology.

[52]  Claude Lenfant,et al.  World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. , 2002, Circulation.

[53]  P. Natarajan,et al.  Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoproteinA-I(Milano). , 2002, Biochemical and biophysical research communications.

[54]  M. Fishbein,et al.  Influenza Infection Promotes Macrophage Traffic Into Arteries of Mice That Is Prevented by D-4F, an Apolipoprotein A-I Mimetic Peptide , 2002, Circulation.

[55]  Aldons J. Lusis,et al.  Identification of macrophage liver X receptors as inhibitors of atherosclerosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Myung‐Sook Choi,et al.  Interaction of CETP inhibitory peptide and lipoprotein substrates in cholesteryl ester transfer assay: Relationship between association properties and inhibitory activities , 2002, Lipids.

[57]  S. Yokoyama,et al.  Helical Apolipoproteins Stabilize ATP-binding Cassette Transporter A1 by Protecting It from Thiol Protease-mediated Degradation* , 2002, The Journal of Biological Chemistry.

[58]  D. Rader,et al.  Characterization of the lipolytic activity of endothelial lipase. , 2002, Journal of lipid research.

[59]  T. Willson,et al.  Synthetic LXR ligand inhibits the development of atherosclerosis in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[60]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[61]  W. Fung-Leung,et al.  Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Timothy M Willson,et al.  Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. , 2002, Journal of medicinal chemistry.

[63]  C. Glass,et al.  Conditional Disruption of the Peroxisome Proliferator-Activated Receptor γ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux , 2002, Molecular and Cellular Biology.

[64]  O. Francone,et al.  Increased Atherosclerosis in Hyperlipidemic Mice With Inactivation of ABCA1 in Macrophages , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[65]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[66]  D. Moller,et al.  A Potent Synthetic LXR Agonist Is More Effective than Cholesterol Loading at Inducing ABCA1 mRNA and Stimulating Cholesterol Efflux* , 2002, The Journal of Biological Chemistry.

[67]  A. von Eckardstein,et al.  HDL and arteriosclerosis: beyond reverse cholesterol transport. , 2002, Atherosclerosis.

[68]  M. Oda,et al.  Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. , 2002, Biochemistry.

[69]  R. Lallone,et al.  Oral Administration of an Apo A-I Mimetic Peptide Synthesized From D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol , 2002, Circulation.

[70]  S. Hampson.  Randomised, placebo-controlled trial , 2002 .

[71]  H. Miyachi,et al.  Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators. , 2002, Bioorganic & Medicinal Chemistry Letters.

[72]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[73]  R. Evans,et al.  Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[74]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[75]  H. Vosper,et al.  The Peroxisome Proliferator-activated Receptor δ Promotes Lipid Accumulation in Human Macrophages* , 2001, The Journal of Biological Chemistry.

[76]  T. Willson,et al.  Chemical genomics: Functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism , 2001, Medicinal research reviews.

[77]  Paul T. Tarr,et al.  Characterization of the Human ABCG1 Gene , 2001, The Journal of Biological Chemistry.

[78]  K. Moore,et al.  Peroxisome proliferator-activated receptors in macrophage biology: friend or foe? , 2001, Current opinion in lipidology.

[79]  B. Lohray,et al.  (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. , 2001, Journal of medicinal chemistry.

[80]  Richard G. W. Anderson,et al.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.

[81]  W. Wilkison,et al.  Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. , 2001, Bioorganic & medicinal chemistry letters.

[82]  D. Shih,et al.  The role of high-density lipoproteins in oxidation and inflammation. , 2001, Trends in cardiovascular medicine.

[83]  G. Anantharamaiah,et al.  A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. , 2001, Journal of lipid research.

[84]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[85]  J. Gustafsson,et al.  Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. , 2001, The Journal of clinical investigation.

[86]  E. Niesor,et al.  The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. , 2001, Current pharmaceutical design.

[87]  Bruce M. Spiegelman,et al.  Obesity and the Regulation of Energy Balance , 2001, Cell.

[88]  J. Auwerx,et al.  Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[89]  O. Francone,et al.  Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. , 2001, The Journal of clinical investigation.

[90]  M. Jaye,et al.  PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.

[91]  Jean-Marc A. Lobaccaro,et al.  Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ , 2000 .

[92]  Masahiro Tohkin,et al.  Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.

[93]  A. Tall,et al.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.

[94]  A. Callow,et al.  Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[95]  K. Wakitani,et al.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.

[96]  E. Rubin,et al.  Relationship between Expression Levels and Atherogenesis in Scavenger Receptor Class B, Type I Transgenics* , 2000, The Journal of Biological Chemistry.

[97]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[98]  J. Ward,et al.  Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ) , 2000, Molecular and Cellular Biology.

[99]  I. Yuhanna,et al.  High Density Lipoprotein Prevents Oxidized Low Density Lipoprotein-induced Inhibition of Endothelial Nitric-oxide Synthase Localization and Activation in Caveolae* , 2000, The Journal of Biological Chemistry.

[100]  V. Pasceri,et al.  Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. , 2000, Circulation.

[101]  D. Mangelsdorf,et al.  Nuclear receptor regulation of cholesterol and bile acid metabolism. , 1999, Current opinion in biotechnology.

[102]  M. Eriksson,et al.  Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. , 1999, Circulation.

[103]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[104]  T. Langmann,et al.  The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease , 1999, Nature Genetics.

[105]  J. Piette,et al.  Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 , 1999, Nature Genetics.

[106]  C. Sensen,et al.  Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency , 1999, Nature Genetics.

[107]  H. Hobbs,et al.  Polyunsaturated fatty acids up-regulate hepatic scavenger receptor B1 (SR-BI) expression and HDL cholesteryl ester uptake in the hamster. , 1999, Journal of lipid research.

[108]  D. Rader,et al.  A novel endothelial-derived lipase that modulates HDL metabolism , 1999, Nature Genetics.

[109]  J. Mehta,et al.  Inhibition of arterial thrombus formation by ApoA1 Milano. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[110]  J. Gamble,et al.  Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. , 1999, Journal of lipid research.

[111]  P. Denéfle,et al.  Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. , 1999, Circulation.

[112]  T. van Gent,et al.  Induction of Adrenal Scavenger Receptor BI and Increased High Density Lipoprotein-Cholesteryl Ether Uptake by in Vivo Inhibition of Hepatic Lipase* , 1998, The Journal of Biological Chemistry.

[113]  V. Laudet,et al.  The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates* , 1998, The Journal of Biological Chemistry.

[114]  A. Tall,et al.  The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. , 1998, Current opinion in structural biology.

[115]  R. Hammer,et al.  Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα , 1998, Cell.

[116]  H. Princen,et al.  No effect of fibrates on synthesis of apolipoprotein(a) in primary cultures of cynomolgus monkey and human hepatocytes: apolipoprotein A-I synthesis increased. , 1998, Biochemical and biophysical research communications.

[117]  T. Kooistra,et al.  Fibrate-modulated Expression of Fibrinogen, Plasminogen Activator Inhibitor-1 and Apolipoprotein A-I in Cultured Cynomolgus Monkey Hepatocytes , 1998, Thrombosis and Haemostasis.

[118]  M. Nieminen,et al.  Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.

[119]  E. Edelman,et al.  Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels , 1997, Nature.

[120]  Alan D. Lopez,et al.  Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.

[121]  G. Dagenais,et al.  Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.

[122]  R. Krauss,et al.  Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. , 1996, JAMA.

[123]  P. Denéfle,et al.  Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. , 1996, Circulation.

[124]  J. Auwerx,et al.  Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. , 1996, The Journal of clinical investigation.

[125]  H. Greten,et al.  Selective uptake of high-density lipoprotein-associated cholesteryl esters by human hepatocytes in primary culture. , 1996, Zeitschrift fur Gastroenterologie.

[126]  Yun-Jing Huang,et al.  Synthesis and Pharmacological Studies of 3‐Amino‐2‐methyl‐1‐phenylpropanones as Hypolipidemic Agents in Rodents , 1996, Archiv der Pharmazie.

[127]  S. Horiuchi,et al.  Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[128]  U. Goldbourt,et al.  Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. , 1995, Journal of Clinical Epidemiology.

[129]  S. Grundy,et al.  Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. , 1994, The Journal of clinical investigation.

[130]  E. Rubin,et al.  Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. , 1994, Journal of lipid research.

[131]  H. Mabuchi,et al.  Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. , 1994, The Journal of clinical investigation.

[132]  J. Breslow,et al.  Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[133]  E. Rubin,et al.  Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. , 1994, The Journal of clinical investigation.

[134]  Lawrence A Leiter,et al.  Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. , 1994, The Journal of clinical investigation.

[135]  A. Tall,et al.  Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles. , 1993, The Journal of biological chemistry.

[136]  G. Assmann,et al.  Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. , 1992, The American journal of cardiology.

[137]  R. Krauss,et al.  Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI , 1991, Nature.

[138]  D. Salem,et al.  Prevalence of risk factors in men with premature coronary artery disease. , 1991, The American journal of cardiology.

[139]  P. Allhoff,et al.  Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle Aged Men with Dyslipidemia , 1991 .

[140]  T. Miller,et al.  Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. , 1991, Mayo Clinic proceedings.

[141]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[142]  A. Tall,et al.  Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins , 1989, Nature.

[143]  G. Rosenhamer,et al.  Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. , 2009, Acta medica Scandinavica.

[144]  G. Assmann,et al.  The Prospective Cardiovascular Münster Study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. , 1987, The American journal of cardiology.

[145]  A. Tall,et al.  Phospholipid liposomes acquire apolipoprotein E in atherogenic plasma and block cholesterol loading of cultured macrophages. , 1987, The Journal of clinical investigation.

[146]  W. H. Heaton,et al.  Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. , 1982, Arteriosclerosis.

[147]  S. Grundy,et al.  Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. , 1981, Journal of lipid research.

[148]  A Kagan,et al.  Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. , 1976, The New England journal of medicine.

[149]  J. Stamler.  Clofibrate and niacin in coronary heart disease. , 1975, JAMA.